Post

AstraZeneca makes another obesity play funnelling $80m into SixPeaks Bio

AstraZeneca has committed to $80m in non-dilutive funding to Swiss biotech SixPeak Bio, which is developing a bispecific antibody therapy …

NICE recommends Rhythm’s Imcivree for rare genetic obesity disorder

As increasing varieties of drugs aimed at weight loss hit the shelves, a new treatment that targets obesity and hunger …

No nitrosamines: How parenteral packaging is evolving to meet today’s E&L challenges

In mid-2018, nitrosamine content (specifically N-nitrosodimethylamine, or NDMA) was found to exceed the guidelines on daily intake limits in a …

How to take advantage of the connected health opportunity in your next drug launch

For a pharmaceutical company that has just navigated a complicated market access journey preceded by ten-plus years of drug development, …

Genmab acquires biotechnology company ProfoundBio in $1.8bn deal

Genmab has concluded the previously announced acquisition of clinical-stage biotechnology company ProfoundBio in a $1.8bn cash transaction. ProfoundBio specialises in the …